Research

Hormonal

Tirzepatide use is associated with a probable risk of acute pancreatitis, characterized by a strong temporal correlation between drug initiation and symptom onset, and clinical resolution upon discontinuation.

If you are taking tirzepatide and develop severe, persistent upper abdominal pain, nausea, or vomiting, stop the medication immediately and seek medical attention. Do not assume the pain is just from gallstones or indigestion, especially if it started shortly after beginning the drug. Early discontinuation can prevent severe complications.

LimitedSupportsLOW confidence
This case raises concerns over the potential risk of pancreatitis associated with tirzepatide use. ... the strong temporal correlation between drug initiation and symptom onset, coupled with clinical resolution upon discontinuation, suggests a probable causal relationship.
Yovan Sumaruth et al. · Cureus · 2025

Why this rating

Based on a single case report (Level 4 evidence), despite a Naranjo score of 5/10 indicating probable causality.

Source

A Probable Case of Tirzepatide-Induced Acute Pancreatitis

Yovan Sumaruth et al. · Cureus · 2025

DOI 10.7759/cureus.85291

case_report · n=1Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →